Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ventyx Biosciences, Sanofi
Ventyx gets $27 million investment from Sanofi
Shares in San Diego-based inflammatory diseases specialist Ventyx Biosciences (Nasdaq: VTYX) rose 8.7% to $2.50 yesterday as it announced that French pharma major Sanofi (Euronext: SAN) has agreed to make a $27 million strategic investment in the company]. The closing of the transaction is expected to occur on September 23, 2024.
Ventyx Biosciences: Cautious Optimism Amidst Sanofi’s Strategic Investment and Upcoming Clinical Trials
H.C. Wainwright analyst Emily Bodnar maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report) today and set a price target
Ventyx stock climbs 8% on $27M Sanofi investment
Ventyx (VTYX) stock jumped 8% on news that Sanofi (SNY) has made a $27M strategic investment in the company at an as-converted price of $3.8243 per common share. Read more here.
Ventyx Biosciences Shares Rise Premarket on Sanofi Investment
Shares of Ventyx Biosciences rose more than 20% in premarket trading after the clinical-stage biopharmaceutical company said it would receive a $27 million from France's Sanofi.
Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi
Ventyx
’s relationship with
Sanofi
may not result in the anticipated positive outcomes; potential delays in the enrollment and completion of clinical trials;
Ventyx
’s dependence on third parties in connection with product manufacturing, research and ...
FierceBiotech
1d
Sanofi scoops negotiation rights to Ventyx obesity, Parkinson's candidate for $27M
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
GlobalData on MSN
1d
Sanofi gains exclusivity rights to Ventyx’s CNS-penetrant drug in $27m deal
Under the terms of the agreement, Sanofi will gain an exclusive right to first negotiation for the CNS-penetrant, VTX3232.
Zacks.com on MSN
16h
VTYX Stock Rises on Strategic Equity Investment Deal With SNY
Shares of Ventyx Biosciences VTYX gained 7% on Monday after the company announced that it has entered into a $27 million ...
ENDPOINTS NEWS
1d
Is Sanofi making a move into obesity? French pharma invests $27M into Ventyx
Sanofi has stayed out of the obesity drug development bonanza, taking a wait-and-see approach while keeping an eye on ...
20h
Metsera touts long-acting GLP-1 drug; Novartis strikes an AI deal
Metsera revealed Phase 1 data it claims could support a weight-loss medicine that's administered monthly. Elsewhere, Sanofi ...
Pharmaceutical Technology
12h
“PBMs favour high list prices”- Novo Nordisk CEO targets PBMs in US Senate hearing
Coverage for its long-acting insulin, Levamir, dropped from 90% to about 35% when the company dropped its list price by 65%.
11h
Sanofi gets binding bids for consumer unit: Bloomberg News
Sanofi (SNY) has won bindings bids for its consumer health division from private equity firms CD&R and PAI Partners. Read ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback